Lv21
108 积分 2024-08-12 加入
Switching to a Fixed-dose Combined Pertuzumab and Trastuzumab With Recombinant Human Hyaluronidase Subcutaneous Injection to Treat Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real-world UK Clinical Practice
24分钟前
待确认
Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan
35分钟前
已完结
Cost-Effectiveness of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in HER2-Positive Early Breast Cancer in China: A Post-Hoc Analysis of the FeDeriCa Trial
8天前
已关闭
Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis
14天前
已完结
Cost-Effectiveness of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in HER2-Positive Early Breast Cancer in China: A Post-Hoc Analysis of the FeDeriCa Trial
15天前
已关闭
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
1个月前
已完结
Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer
1个月前
已完结
114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
2个月前
已关闭
Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer’s Disease: A U.S. Cost Comparison Model
4个月前
已完结
皖公网安备34019202002308
